Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain-Reference-Cited by-同舟云学术

Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain

Published:2018-06-26 Issue:15 Volume:61 Page:6779-6800
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bagal Sharan K.¹^ORCID,Andrews Mark²,Bechle Bruce M.³,Bian Jianwei³,Bilsland James⁴,Blakemore David C.¹,Braganza John F.⁵,Bungay Peter J.⁶,Corbett Matthew S.³,Cronin Ciaran N.⁵,Cui Jingrong Jean⁵,Dias Rebecca⁴,Flanagan Neil J.⁴,Greasley Samantha E.⁵,Grimley Rachel⁴,James Kim⁷,Johnson Eric⁵,Kitching Linda⁴,Kraus Michelle L.⁵,McAlpine Indrawan⁵,Nagata Asako⁵,Ninkovic Sacha⁵,Omoto Kiyoyuki¹,Scales Stephanie⁵,Skerratt Sarah E.¹,Sun Jianmin³,Tran-Dubé Michelle⁵,Waldron Gareth J.⁴,Wang Fen⁵,Warmus Joseph S.³

Affiliation:

1. Worldwide Medicinal Chemistry, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.

2. Pfizer Worldwide R&D U.K., Sandwich, Kent CT13 9NJ, U.K.

3. Pfizer Worldwide R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States

4. Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.

5. Pfizer Worldwide R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States

6. Pharmacokinetics, Dynamics & Metabolism, Pfizer Worldwide R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.

7. Peakdale Molecular, Discovery Park House, Ramsgate Road, Sandwich CT13 9ND, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00633

Reference51 articles.

1. The Neurotrophin Family of Neurotrophic Factors: An Overview

2. Novel class of pain drugs based on antagonism of NGF

3. Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee

4. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain

5. Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Hit to Lead Optimization of Macrocyclic Peptides as Novel Tropomyosin Receptor Kinase A Antagonists;Journal of Medicinal Chemistry;2024-07-01

2. Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update;Expert Opinion on Therapeutic Patents;2024-04-02

3. Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling;Current Cancer Drug Targets;2024-03

4. Synthesis and Antiproliferative Activity of 2-Oxo-4-Cyano-1,2-Dihydropyridine-3-Carboxamides;Pharmaceutical Chemistry Journal;2023-11

5. Neuropathic pain; what we know and what we should do about it;Frontiers in Pain Research;2023-09-22